ArticlemedRxiv : the preprint server for health sciences2024

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone.

Omar Nadeem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.